Triple M syndrome (myasthenia gravis, myocarditis and myositis) following atezolizumab in small cell lung carcinoma - PubMed
6 hours ago
- #small cell lung carcinoma
- #immune checkpoint inhibitor
- #Triple M syndrome
- An older adult in his early 80s with locally advanced small cell lung carcinoma developed Triple M syndrome (myasthenia gravis, myocarditis, and myositis) after treatment with carboplatin, etoposide, and atezolizumab.
- The patient exhibited acute ocular and neuromuscular symptoms after two cycles of treatment, leading to a diagnosis of immune checkpoint inhibitor-related Triple M syndrome.
- Treatment with high-dose corticosteroids and pyridostigmine was effective, though prolonged rehabilitation was required.
- Despite the severe immune-related adverse events, the patient showed an excellent radiological response to the systemic therapy.
- This case underscores the importance of vigilance for severe neuromuscular and cardiac immune-related adverse events, prompt multidisciplinary management, and the challenge of balancing cancer control with potential life-threatening toxicity.